CytomX Therapeutics, Inc. (CTMX) revenue

Revenue · fiscal 2025
$76.20M

CytomX Therapeutics, Inc. (CTMX) reported revenue of $76.20M in fiscal 2025 (the year ended December 31, 2025). That is 44.8% lower than the $138.10M of fiscal 2024. Figures as of 18 Nov 2026, 07:19 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$76.20M
Change on fiscal 2024
−44.8%
Growth, 5 years
+2.2% a year
Growth, 10 years
+25.7% a year
Highest on record
$138.10Mfiscal 2024
Lowest on record
$888.00Kfiscal 2013
Fiscal years on record
132013–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

CytomX Therapeutics, Inc. revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 2.2% a year; over ten years the rate was 25.7% a year. Across the 13 fiscal years on record (2013–2025), the highest was $138.10M in fiscal 2024 and the lowest $888.00K in fiscal 2013.

History · 13 fiscal years

Revenue by fiscal year

CytomX Therapeutics, Inc. revenue, year by year

CytomX Therapeutics, Inc. (CTMX) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$76.20M 44.8% down
2024$138.10M 36.4% up
2023$101.21M 90.4% up
2022$53.16M 42.5% up
2021$37.31M 45.5% down
2020$68.43M 154.4% up
2019$26.90M 54.8% down
2018$59.50M 16.9% down
2017$71.62M 457.6% up
2016$12.85M 66.6% up
2015$7.71M 51.9% up
2014$5.08M 471.7% up
2013$888.00K—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

More on CTMX

CytomX Therapeutics, Inc., figure by figure

CytomX Therapeutics, Inc. (CTMX) overview: price, valuation and scorecard

CytomX Therapeutics, Inc. revenue: questions and answers

What is CytomX Therapeutics, Inc.'s revenue?

CytomX Therapeutics, Inc. (CTMX) reported revenue of $76.20M in fiscal 2025 (the year ended December 31, 2025). That is 44.8% lower than the $138.10M of fiscal 2024.

What is the growth rate of CytomX Therapeutics, Inc.'s revenue?

Over the five fiscal years to 2025 revenue grew at a compound 2.2% a year; over ten years the rate was 25.7% a year.

What are the highest and lowest revenue figures on record for CytomX Therapeutics, Inc.?

Across the 13 fiscal years on record (2013–2025), the highest was $138.10M in fiscal 2024 and the lowest $888.00K in fiscal 2013.

How is CytomX Therapeutics, Inc.'s revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “CytomX Therapeutics, Inc. (CTMX) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/CTMX/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.